CDT (CDT Equity) Other Operating Expense: $-0.10 Mil (TTM As of Dec. 2025)


CDT CDT Equity Inc CDT
10 GF Score
Price $0.45
! 5 Warning Signs
View Full Analysis

What is CDT Equity Other Operating Expense?

CDT Equity CDT -8.06% 10 Other Operating Expense is $-0.10 Mil as of Dec. 2025. GuruFocus rates CDT with a GF Score™ of 10/100. The stock has 5 warning signs investors should review.

CDT Equity's Other Operating Expense for the three months ended in Dec. 2025 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.10 Mil.

CDT Equity's quarterly Other Operating Expense declined from Jun. 2025 ($-0.00 Mil) to Sep. 2025 ($-0.10 Mil) but then increased from Sep. 2025 ($-0.10 Mil) to Dec. 2025 ($0.00 Mil).

CDT Equity's annual Other Operating Expense declined from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($-0.31 Mil) but then increased from Dec. 2024 ($-0.31 Mil) to Dec. 2025 ($-0.10 Mil).

CDT Equity Other Operating Expense Historical Data

* Premium members only.

The historical data trend for CDT Equity's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CDT Equity Other Operating Expense Chart

CDT Equity Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
0.00 0.00 0.00 -0.31 -0.10

CDT Equity Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.31 0.00 -0.00 -0.10 0.00
CDT
10GF Score
CDT Equity Inc CDT
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CDT Equity Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.10 Mil mean?
CDT Equity (CDT) has a Other Operating Expense of $-0.10 Mil as of Dec. 2025. Other operating expenses that a company records on its income statement. View historical data on CDT Equity and its competitors.
Is CDT Equity's Other Operating Expense too high?
CDT Equity's current Other Operating Expense is $-0.10 Mil. Overall, CDT Equity has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does CDT Equity's Other Operating Expense compare to CLDI and DCOY?
CDT Equity's Other Operating Expense of $-0.10 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on CDT Equity and its competitors. CDT Equity's current Other Operating Expense is $-0.10 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CDT Equity stock overvalued right now?
CDT Equity (CDT) has a current Other Operating Expense of $-0.10 Mil. The current Other Operating Expense is $-0.10 Mil. CDT Equity's overall GF Score™ is 10/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For CDT Equity (CDT), the current Other Operating Expense is $-0.10 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CDT Equity Business Description

Address 4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
CDT Equity Inc is a data-driven biopharmaceutical development company focused on identifying, enhancing, and advancing high-potential therapeutic assets through scientific innovation and strategic partnerships. It has evolved into a broader, more agile platform that leverages artificial intelligence, solid-form chemistry, and efficient asset repositioning to accelerate the development of novel treatments. The company's pipeline includes candidates that target autoimmune disorders, as well as idiopathic male infertility, oncology, dermatology, rare disease and animal health. It has one operating segment focused on the research and development of clinical assets.
10GF Score

Get the complete analysis for CDT

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.45
Price